2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Renal Cell
65
Kidney Neoplasms
18
Neoplasms
16
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Carcinoma, Hepatocellular
8
Carcinoma
8
Melanoma
7
Glioblastoma
5
Clear-cell metastatic renal cell carcinoma
5
Lung Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Skin Neoplasms
2
Sarcoma
2
Pheochromocytoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Paraganglioma
2
Liver Neoplasms
2
Kidney Diseases
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms
2
Advanced Solid Tumors
2
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Axitinib
×
Clear all
NCT01211275
2017-02-28
N08CPA
The Netherlands Cancer Institute
Phase 1/2
Completed
32 enrolled